| Ytd | -62.75% | |
| 1y | -31.65% |
| Open | 0.49 | Prev Close | 0.48 | Low | 0.48 | High | 0.49 | Mkt Cap | 16.06M |
| Vol | 39.65K | Avg Vol | 794.05K | EPS | -1.60 | P/E | -0.30 | Forward P/E | -3.75 |
| Beta | 0.82 | Short Ratio | 0.32 | Inst. Own | 2.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-16 | 50-d Avg | 0.51 | 200-d Avg | 0.76 | 1yr Est | 2.00 |
Oncobiologics (NASDAQ: OTLK - Get Free Report) and Pasithea Therapeutics (NASDAQ: KTTA - Get Free Re
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK In
On Friday, 469 companies hit new 52-week lows.
On Wednesday, 479 stocks made new 52-week lows.